Thompson Chris
University of Southampton, Mental Health Group, Faculty of Medicine, Health and Biological Sciences, Southampton, UK.
Hum Psychopharmacol. 2002 Jun;17 Suppl 1:S27-32. doi: 10.1002/hup.386.
Because the value of antidepressants is hampered by their delay in onset of action, considerable attention has been focused on developing a drug that acts more rapidly. However, although specific studies are now ongoing, there have been no peer-reviewed prospective onset of action trials published in the literature to date. Some data are currently available from post-hoc pooled analyses and numerous methods have been developed for evaluating the onset of action; these include the time to response, the time to onset of therapeutic effect, pattern analysis and survival analyses. Such an analysis of four large-scale, double-blind studies has provided evidence for an earlier onset of action with mirtazapine than with the SSRIs (fluoxetine, paroxetine and citalopram). Significant differences were seen between mirtazapine and the SSRIs after 1 week of treatment. This effect was consistent across the four different methodologies and appears to be due to a specific antidepressant effect rather than an early effect on, for example, sleep. These findings await confirmation from specifically designed prospective onset of action studies.
由于抗抑郁药起效延迟限制了其疗效,因此开发起效更快的药物受到了广泛关注。然而,尽管目前正在进行具体研究,但迄今为止,尚无经同行评审的前瞻性起效试验发表于文献中。目前可从事后汇总分析中获得一些数据,并且已经开发出多种评估起效时间的方法;这些方法包括起效时间、治疗效果起效时间、模式分析和生存分析。对四项大规模双盲研究的此类分析表明,米氮平比选择性5-羟色胺再摄取抑制剂(氟西汀、帕罗西汀和西酞普兰)起效更早。治疗1周后,米氮平与选择性5-羟色胺再摄取抑制剂之间出现显著差异。这种效应在四种不同方法中是一致的,并且似乎是由于特定的抗抑郁作用,而非例如对睡眠的早期作用。这些发现有待专门设计的前瞻性起效研究加以证实。